● Recruiting

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Condition: Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

PhasePhase 3

Planned participants450

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06994195